公开(公告)号：US20230218748A1

公开(公告)日：2023-07-13

申请号：US17416306

申请日：2019-12-19

Applicant: UNITED BIOMEDICAL, INC.

Inventor： Chang Yi WANG

IPC: A61K39/245 ,  C07K14/47 ,  A61K39/21 ,  A61K39/135 ,  A61K39/12 ,  A61K39/187 ,  A61P31/22 ,  A61P31/18 ,  A61P31/14

CPC classification number: A61K39/245 ,  C07K14/47 ,  A61K39/21 ,  A61K39/135 ,  A61K39/12 ,  A61K39/187 ,  A61P31/22 ,  A61P31/18 ,  A61P31/14 ,  A61K2039/6031

Abstract: The present invention is directed to novel promiscuous and artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity of a target antigenic site. The target antigenic site can include a B cell epitope, a CTL epitope, a peptide hapten, a non-peptide hapten, or any immunologically reactive analogue thereof. The disclosed Th epitopes, when covalently linked to a target antigenic site in a peptide immunogen construct, elicit a strong B cell antibody response or an effector T cell response to the target antigenic site. The Th epitopes are immunosilent on their own, i.e., little, if any, of the antibodies generated by the peptide immunogen constructs will be directed towards the Th epitope, thus allowing a very focused immune response directed to the targeted antigenic site. The promiscuous artificial Th epitopes provide effective and safe peptide immunogens that do not generate inflammatory, anti-self, cell-mediated immune responses following administration.

公开(公告)号：US11672856B2

公开(公告)日：2023-06-13

申请号：US16910845

申请日：2020-06-24

Applicant: CureVac AG

Inventor： Karl-Josef Kallen ,  Thomas Kramps ,  Margit Schnee ,  Benjamin Petsch ,  Lothar Stitz

IPC: A61K39/145 ,  A61K39/155 ,  A61K39/12 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61P31/16 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K45/06 ,  A61K47/59 ,  A61K47/6455 ,  A61K47/6921 ,  A61P31/16 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/622 ,  C12N2760/16134 ,  C12N2760/18534 ,  C12N2760/18571 ,  Y02A50/30

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

公开(公告)号：US11654189B2

公开(公告)日：2023-05-23

申请号：US17367528

申请日：2021-07-05

Applicant: Bavarian Nordic A/S

Inventor： Markus Kalla ,  Ryan Rountree ,  Ulrike Dirmeier

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  C07K1/00 ,  A61K39/285 ,  C07K14/47 ,  C07K14/705 ,  C12N15/863

CPC classification number: A61K39/0011 ,  A61K39/00117 ,  A61K39/001182 ,  C07K14/4727 ,  C07K14/70525 ,  C07K14/70528 ,  C07K14/70532 ,  C12N15/863 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/6031 ,  C12N2710/24143

Abstract: Provided herein are recombinant poxviruses that are stable through successive passaging of the recombinant poxviruses. More particularly, the recombinant poxviruses comprise one or more modified nucleic acids encoding MUC1, CEA, and/or TRICOM antigens, wherein the recombinant poxviruses are stable through successive passaging. Also, provided herein are compositions and method related thereto.

公开(公告)号：US20190231859A1

公开(公告)日：2019-08-01

申请号：US16211492

申请日：2018-12-06

Applicant: GlobeImmune, Inc. ,  The USA, as represented by the Secretary, Dept. of Health and Human Services

Inventor： Alex Franzusoff ,  Zhimin Guo ,  Jeffrey Schlom ,  Kwong-Yok Tsang

IPC: A61K39/00 ,  A61K31/65 ,  A61K35/17 ,  A61K35/13 ,  C07K14/47 ,  A61K35/28 ,  A61K31/704 ,  A61K31/7068

CPC classification number: A61K39/0011 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7068 ,  A61K35/13 ,  A61K35/17 ,  A61K35/28 ,  A61K39/0002 ,  A61K2039/523 ,  A61K2039/525 ,  A61K2039/6031 ,  C07K14/4727

Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).

公开(公告)号：US20190216912A1

公开(公告)日：2019-07-18

申请号：US16371020

申请日：2019-03-31

Applicant: Lior CARMON ,  VAXIL BIOTHERAPEUTICS LTD.

Inventor： Lior CARMON

IPC: A61K39/04

CPC classification number: A61K39/04 ,  A61K2039/6031 ,  A61K2039/6068 ,  A61K2039/6075 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414

Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

公开(公告)号：US20190184013A1

公开(公告)日：2019-06-20

申请号：US16302457

申请日：2017-05-23

Applicant: University of Miami

Inventor： Victor L. Perez Quinones ,  Pirouz Daftarian

IPC: A61K39/395 ,  C07K14/47 ,  A61P31/00 ,  A61P35/00 ,  A61P29/00 ,  A61P37/00 ,  A61K47/50 ,  A61K9/51

CPC classification number: A61K39/39558 ,  A61K9/51 ,  A61K39/39 ,  A61K47/50 ,  A61K47/595 ,  A61K47/643 ,  A61K47/646 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/6031 ,  A61K2039/645 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  C07K14/47 ,  C12N5/163

Abstract: Conjugates of synthetic nanocarriers, complexed with syngeneic (self) proteins adducted with haptens or other poorly immunogenic antigens (antigens of low immunogenicity), elicit selective humoral responses or antibodies against the hapten or antigen and not to self-protein. Compositions include these conjugates, which can be used as vaccines. Methods of making and using them are described herein. In a typical embodiment, a conjugate including a hapten or antigen of low immunogenicity associated with a particular disease (e.g., infection, cancer) can be used as a vaccine by eliciting antibodies that specifically neutralize the hapten or antigen. These hapten (and other poorly immunogenic antigen)-carrying nanocarriers selectively target antigen presenting cells resulting in a strong anti-hapten humoral response, and thus find use in vaccines for cancer (e.g., cancers of lung, cervix, breast, brain, liver pancreas, ovaries, skin, etc.), infectious diseases and inflammatory-mediated diseases, as well as for autoimmune disorders.

公开(公告)号：US20180264097A1

公开(公告)日：2018-09-20

申请号：US15981950

申请日：2018-05-17

Applicant: Virginia Commonwealth University

Inventor： Jason A. Carlyon

IPC: A61K39/02

CPC classification number: A61K39/0233 ,  A61K39/40 ,  A61K2039/55566 ,  A61K2039/6031 ,  A61K2039/6081 ,  A61K2039/70 ,  C07K16/1246 ,  C07K2317/76 ,  G01N33/56911 ,  G01N33/56983 ,  G01N2333/195 ,  G01N2333/29 ,  G01N2469/10 ,  G01N2800/42 ,  Y02A50/403

Abstract: Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.

公开(公告)号：US10076563B2

公开(公告)日：2018-09-18

申请号：US15131674

申请日：2016-04-18

Applicant: Inventprise, LLC

Inventor： Subhash V. Kapre ,  Francis Michon

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/39

CPC classification number: A61K39/099 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/575 ,  A61K2039/58 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  A61K2039/627 ,  A61K2039/70

Abstract: This invention is directed to composition, vaccines, tools and methods in the treatment and prevention of Bordetella pertussis. In particular, the invention is directed to a three-pronged approach that involves removal of the nonessential vaccine components, use of a nondenatured, genetically detoxified mutant, and adding virulence factors.

公开(公告)号：US10071150B2

公开(公告)日：2018-09-11

申请号：US15111758

申请日：2015-01-15

Applicant: SHENZHEN TAILAI BIOPHARMACEUTICALS, LLC

Inventor： Tao Bian ,  Juan Li ,  Xiao Xiao

IPC: A61K39/12 ,  C07K14/025 ,  C07K14/35 ,  C07K14/535 ,  C07K14/54 ,  A61K39/39 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61K2039/6031 ,  A61K2039/6043 ,  C07K14/005 ,  C07K14/35 ,  C07K14/535 ,  C12N7/00 ,  C12N2710/10343 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071

Abstract: An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.

公开(公告)号：US20180237487A1

公开(公告)日：2018-08-23

申请号：US15957282

申请日：2018-04-19

Applicant: OpSaniTx LLC

Inventor： Andrew SEGAL ,  Elihu Young

IPC: C07K14/535 ,  C07K14/005 ,  A61K39/00

CPC classification number: C07K14/535 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/5152 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55527 ,  A61K2039/6031 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/33 ,  C12N2760/16034 ,  C12N2760/16134

Abstract: The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.